70842-225-01 : NDC 2026 Code

70842-225-01 : Oritavancin Diphosphate ( Kimyrsa )

Additionally :

You can get information about “70842-225-01” NDC code in 70842-225-01 in HTML format

HTML | 70842-225-01 in TXT (Plain Text) format

TXT | 70842-225-01 in PDF (Portable Document Format)

PDF | 70842-225-01 in XML format

XML formats.

NDC Code : 70842-225-01 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "70842-225-01",
    "PackageDescription": "1 VIAL in 1 CARTON (70842-225-01)  / 40 mL in 1 VIAL",
    "NDC11Code": "70842-0225-01",
    "ProductNDC": "70842-225",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Kimyrsa",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Oritavancin Diphosphate",
    "DosageFormName": "INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION",
    "RouteName": "INTRAVENOUS",
    "StartMarketingDate": "20210323",
    "EndMarketingDate": null,
    "MarketingCategoryName": "NDA",
    "ApplicationNumber": "NDA214155",
    "LabelerName": "Melinta Therapeutics, LLC",
    "SubstanceName": "ORITAVANCIN DIPHOSPHATE",
    "StrengthNumber": "1200",
    "StrengthUnit": "mg/40mL",
    "Pharm_Classes": "Cytochrome P450 2C19 Inhibitors [MoA], Cytochrome P450 2C9 Inhibitors [MoA], Cytochrome P450 2D6 Inducers [MoA], Cytochrome P450 3A4 Inducers [MoA], Lipoglycopeptide Antibacterial [EPC], Lipoglycopeptides [CS]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-12-20",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20210323",
    "EndMarketingDatePackage": null,
    "SamplePackage": "N"
  }
}